Deal on the horizon for Medicure's heart drug?

Medicure says several partners have expressed interest in its heart drug Aggrastat. The company has brought in Canadian life science investment firm Bloom Burton & Co to help Medicure with financial alternatives and fundraising, while Beal Advisors Help arrange the potential partnership, license, or sale of the drug.*

Aggrastat, which was originally developed by Merck, is an antiplatlet drug that competes in the U.S. with ReoPro and Integrilin. Medicure bought the drug from MGI Pharma for $19 million and is looking to grab a bigger chunk of its markets. However, Medicure says further studies of the drug are needed so that healthcare professionals can become more comfortable prescribing the drug. The company hopes its discussions with potential partners will lead to the financing necessary to carry out further trials.

- check out Medicure's statement
- read the Winnipeg Free Press report

*Editor's Note: This article incorrectly stated that Bloom Burton, not Beal Advisors, would help arrange the partnership, license, or sale of the drug.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.